id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3534-0006,FDA,FDA-2024-E-3534,Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T19:56:16Z,2026-02974,1,0,09000064b91a9ffc
FDA-2024-E-3534-0005,FDA,FDA-2024-E-3534,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T20:32:50Z,,0,0,09000064b90ab173
FDA-2024-E-3534-0004,FDA,FDA-2024-E-3534,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T21:55:43Z,,0,0,09000064b90691a0
FDA-2024-E-3534-0003,FDA,FDA-2024-E-3534,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-12T04:00:00Z,2025,8,2025-08-12T04:00:00Z,,2025-08-13T00:25:23Z,,0,0,09000064b8ef8d84
FDA-2024-E-3534-0001,FDA,FDA-2024-E-3534,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:34:21Z,,0,0,090000648660a4c0
FDA-2024-E-3534-0002,FDA,FDA-2024-E-3534,"Patent Extension Application from Morgan, Lewis & Bockius LLP (on behalf of lovance Biotherapeutics, Inc. (""lovance""))",Other,Application,2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:35:13Z,,0,0,090000648660b1b8